Age-less by Design: Inside the Cell's Peptide Factory

Age-less or Overhyped? The Sixty-Year Cerebrolysin Puzzle | The Age-Less Top 20 Peptides

Episode summary Cerebrolysin is a peptide preparation with a strange résumé: developed in Austria more than sixty years ago, approved in nearly fifty countries for stroke, traumatic brain injury, and dementia, put through hundreds of clinical trials — and yet still surrounded by a genuinely unresolved question about whether it works. In this episode we unpack what it actually is (not a single peptide, but a standardized mixture of amino acids and small fragments made by enzymatically digesting pig brain tissue), the one clever idea at its core (fragments small enough to slip across the blood-brain barrier and mimic the brain's own neurotrophic factors like BDNF and NGF), and the crucial gap between an effect in a lab dish and a real benefit in a human being. Then we get to the part the marketing skips. A 2023 systematic review found Cerebrolysin likely offers no benefit for survival in acute ischemic stroke and may even raise the rate of serious adverse events — and much of the supportive research has been funded by the manufacturer. We also cover the uncomfortable reality behind the vials sold online: it's not FDA-approved in the US, and the "research use only" label is a legal workaround for shipping an unregulated injectable with no purity or sterility guarantees. The takeaway is neither hype nor dismissal — Cerebrolysin is a genuinely interesting compound aimed at a real target, but the honest evidence says it's worth watching, not worth self-experimenting on with a needle. As always: not medical advice, and a real conversation for a licensed physician.

Age-less by Design: Inside the Cell's Peptide Factory

Episode summary Right now, inside every cell in your body, trillions of microscopic factories are assembling molecules called peptides — the short chains of amino acids your body uses to talk to itself, from insulin to oxytocin. But how does your body actually build one? In this episode we follow a single peptide all the way from blueprint to finished product, using the real scientific terms but giving you a picture for every one. We start in the "library" of your DNA, where each recipe is written in three-letter words called codons, then watch the cell make a disposable photocopy — messenger RNA — so the precious original never has to leave. That copy travels to the ribosome, the cell's assembly line, where a fleet of molecular "delivery trucks" brings exactly the right amino acids and snaps them into a chain, bead by bead. But coming off the assembly line isn't the finish line. We walk through the finishing shop — where the floppy chain folds into its working shape, gets reinforced with molecular "staples," and is often trimmed down from an oversized version (the surprising way your body actually builds insulin) — and then the packaging and shipping department that releases the final peptide out into your body. We close by zooming out to nature's other method of building peptides without a ribosome at all (the route behind many antibiotics), and how humans manufacture peptides ourselves, from building them one bead at a time in the lab to turning engineered bacteria into living insulin factories. By the end, you'll understand one of the most elegant manufacturing processes in the known universe — the one that's been running inside you your whole life.

Age-Less LL-37: The Antibiotic in Your Blood | The Age-Less Top 20 Peptides

LL-37 is the odd one out in the Age-Less peptide series. Where Humanin and MOTS-c were mitochondrial longevity signals, LL-37 is the human cathelicidin — your body's own broad-spectrum antibiotic, a small positively charged peptide cut from a larger precursor and stationed at every barrier where you meet the outside world. Dr. Ethan walks through what it actually is: how it's encoded, how it's stored and released, and how that little two-faced helix kills bacteria on contact, neutralizes endotoxin, recruits immune cells, heals wounds, and links your innate immunity to your vitamin D status. Then he turns the coin over. LL-37 is genuinely double-edged — a superb defender when it fires correctly, and a documented driver of disease when it doesn't. This episode lays out the mechanisms behind its role in psoriasis, rosacea, and lupus, explains why "more is better" is exactly the wrong instinct here, and separates the strong evidence for your own endogenous LL-37 from the thin, narrow evidence for LL-37 as an administered therapy. Along the way: the real vitamin D connection (and why supplementing on top of sufficiency won't reliably raise it), and why a regulator has specifically flagged this molecule as a safety concern. The honest bottom line runs opposite to the marketing. This isn't a level to chase or a peptide to inject — it's a system to keep in good working order. No hype, no discount codes: just what LL-37 is, what it does, what the human data shows, and what the regulatory picture actually looks like in 2026. One note: I kept the title's framing accurate to the science (the "shouldn't inject" line reflects the real safety picture, not editorializing). If you'd prefer something shorter or more neutral for a feed, say the word and I'll trim it.

Age-Less Protection: The Real Science of Humanin | The Age-Less Top 20 Peptides

In this episode of The Science of Age-less Living, Dr. Ethan Hausman-Marquis unpacks Humanin — a molecule with one of the most remarkable origin stories in longevity science. Discovered in 2001 in the surviving neurons of an Alzheimer's-affected brain, Humanin turned out to be encoded not in our nuclear DNA but inside the mitochondrial genome, making it the founding member of an entirely new class of molecules: the mitochondrial-derived peptides. It reframed the mitochondrion as more than a power plant — as a sensor that, under stress, sends peptide messages to the rest of the body. Dr. Hausman-Marquis walks through what Humanin actually is, its two forms, and its well-characterized protective biology: blocking apoptosis by neutralizing pro-death Bcl-2 proteins, signaling through a trimeric cell-surface receptor to activate survival pathways, engaging the IGF-1 axis, and improving insulin sensitivity. Then comes the honest reckoning. Humanin declines substantially with age, tracks with better outcomes in observational data, and runs high in the children of centenarians — but the human evidence largely stops there. There are no completed efficacy trials, no approved product, and no established dose, and much of the most impressive preclinical work relied on a synthetic analog roughly a thousand times more potent than the natural peptide. The episode separates the compelling biology from the near-blank clinical page, covers the evidence-based ways to support Humanin naturally — exercise, caloric discipline, and mitochondrial health — and closes with a look ahead to MOTS-c, the second major mitochondrial-derived peptide. No hype, no discount codes — just the science, as it actually stands in 2026.

Age-Less Energy: The Real Science of SS-31 | Age-Less Top 20 Peptides

SS-31 — also known as elamipretide — occupies a category no other compound in this series can claim: it is the first mitochondria-targeted therapy ever to receive FDA approval. In this episode, Dr. Ethan traces the compound from its accidental discovery in a Weill Cornell pharmacology lab through to its September 2025 accelerated approval for Barth syndrome, unpacking the biology of cardiolipin — the inner mitochondrial membrane phospholipid whose decline with age sits at the centre of SS-31's entire mechanistic rationale — and explaining precisely why a peptide that concentrates over 1,000-fold inside the mitochondrial membrane represents a genuinely novel class of therapeutic tool. The mechanism is well-supported, the preclinical literature is large and independently replicated, and the clinical trial programme is the most rigorous of any compound covered in this series so far. The honest picture is more nuanced than the approval alone would suggest. The regulatory journey was long and difficult — an initial refusal to file, a subsequent rejection, and an eventual accelerated approval based on an intermediate endpoint in a rare paediatric disease population. The heart failure and AMD programmes remain in active development, not yet approved. And for the application most longevity-focused listeners are actually interested in — preserving mitochondrial function in a healthy ageing adult — there are no completed trials and no approved protocols. Dr. Ethan draws a precise line between what the approval actually means, what the active trial pipeline shows, and where the extrapolation to healthy ageing begins — and explains why SS-31 is simultaneously the most clinically credible mitochondrial compound in the longevity space and still some distance from a validated longevity intervention.